CO5580794A2 - Conjugados de hormona de crecimiento humana modificada quimicamente - Google Patents

Conjugados de hormona de crecimiento humana modificada quimicamente

Info

Publication number
CO5580794A2
CO5580794A2 CO04046633A CO04046633A CO5580794A2 CO 5580794 A2 CO5580794 A2 CO 5580794A2 CO 04046633 A CO04046633 A CO 04046633A CO 04046633 A CO04046633 A CO 04046633A CO 5580794 A2 CO5580794 A2 CO 5580794A2
Authority
CO
Colombia
Prior art keywords
conjugate
poly
amino acid
ethylene glycol
molecule
Prior art date
Application number
CO04046633A
Other languages
English (en)
Spanish (es)
Inventor
F Finn Roy
Liao Wei
R Siegel Ned
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5580794A2 publication Critical patent/CO5580794A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormones [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CO04046633A 2001-11-20 2004-05-20 Conjugados de hormona de crecimiento humana modificada quimicamente CO5580794A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
CO5580794A2 true CO5580794A2 (es) 2005-11-30

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04046633A CO5580794A2 (es) 2001-11-20 2004-05-20 Conjugados de hormona de crecimiento humana modificada quimicamente

Country Status (25)

Country Link
EP (1) EP1453859A2 (zh)
JP (2) JP2005525302A (zh)
KR (2) KR20050044858A (zh)
CN (1) CN1608079A (zh)
AP (1) AP2004003050A0 (zh)
AU (1) AU2002356990A1 (zh)
BR (1) BR0214451A (zh)
CA (1) CA2467731A1 (zh)
CO (1) CO5580794A2 (zh)
EA (2) EA008505B1 (zh)
EC (1) ECSP045114A (zh)
GE (1) GEP20063860B (zh)
HR (1) HRP20040448A2 (zh)
HU (1) HUP0500997A2 (zh)
IL (1) IL162031A0 (zh)
IS (1) IS7268A (zh)
MA (1) MA27544A1 (zh)
MX (1) MXPA04004809A (zh)
NO (1) NO20042182L (zh)
OA (1) OA13063A (zh)
PL (1) PL374354A1 (zh)
RS (1) RS53104A (zh)
TN (1) TNSN04090A1 (zh)
WO (1) WO2003044056A2 (zh)
ZA (1) ZA200403907B (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100964411B1 (ko) * 2002-01-18 2010-06-15 바이오겐 아이덱 엠에이 인코포레이티드 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US7157546B2 (en) 2002-09-09 2007-01-02 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
ES2349743T3 (es) * 2003-10-10 2011-01-11 Novo Nordisk A/S Derivados de la il-21.
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
RU2385879C2 (ru) * 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
AP2007003919A0 (en) * 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
SG161210A1 (en) * 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
KR20070090023A (ko) * 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
DK2399893T3 (en) * 2004-12-22 2018-10-08 Ambrx Inc COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
EP1877439B1 (en) 2005-04-18 2011-02-09 Novo Nordisk A/S Il-21 variants
AU2006286486A1 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
RS51998B (en) * 2005-11-08 2012-04-30 Ambrx Inc. ACCELERATORS FOR MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES
EP1968635B1 (en) 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2007271150A1 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
ES2453946T3 (es) 2008-04-03 2014-04-09 Biosteed Gene Expression Tech. Co., Ltd. Hormona del crecimiento modificada con polietilenglicol bicatenario, método de preparación y aplicación de esta
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
JP5639585B2 (ja) * 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション ペプチド−ポリマー共役体
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
TWI508737B (zh) 2010-01-22 2015-11-21 諾佛 儂迪克股份有限公司 具有延長的活體內功效的生長激素
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
EP4282485A3 (en) 2014-11-06 2024-01-17 PharmaEssentia Corporation Dosage regimen for pegylated interferon
IL254389B2 (en) * 2015-03-11 2023-03-01 Nektar Therapeutics Polymer conjugates and the il–7 group
SG11201802180TA (en) 2015-09-18 2018-04-27 Univ Miyazaki Long-acting adrenomedullin derivative
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69635026T2 (de) * 1995-09-21 2006-05-24 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2204509T3 (es) * 1999-01-29 2004-05-01 F. Hoffmann-La Roche Ag Conjugados de gcsf.
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
EA200700431A1 (ru) 2008-02-28
OA13063A (en) 2006-11-10
KR20050044858A (ko) 2005-05-13
PL374354A1 (en) 2005-10-17
MXPA04004809A (es) 2004-08-11
EP1453859A2 (en) 2004-09-08
HUP0500997A2 (en) 2007-11-28
TNSN04090A1 (fr) 2006-06-01
JP2005525302A (ja) 2005-08-25
BR0214451A (pt) 2006-05-30
CN1608079A (zh) 2005-04-20
JP2006321808A (ja) 2006-11-30
HRP20040448A2 (en) 2006-02-28
AU2002356990A1 (en) 2003-06-10
IL162031A0 (en) 2005-11-20
WO2003044056A2 (en) 2003-05-30
ECSP045114A (es) 2004-07-23
RS53104A (en) 2006-10-27
IS7268A (is) 2004-05-17
EA200400565A1 (ru) 2005-06-30
ZA200403907B (en) 2007-12-27
CA2467731A1 (en) 2003-05-30
AP2004003050A0 (en) 2004-06-30
MA27544A1 (fr) 2005-10-03
NO20042182L (no) 2004-08-11
KR20070072924A (ko) 2007-07-06
WO2003044056A3 (en) 2003-08-21
EA008505B1 (ru) 2007-06-29
GEP20063860B (en) 2006-06-26

Similar Documents

Publication Publication Date Title
CO5580794A2 (es) Conjugados de hormona de crecimiento humana modificada quimicamente
AU724326B2 (en) Peptide prodrugs containing an alpha-hydroxyacid linker
JP2003521937A5 (zh)
AR036865A1 (es) Conjugado molecular ionico de poliesteres biodegradables y polipeptidos bioactivos
RU2002120486A (ru) Свободная от агрегатов уратоксидаза для приготовления неиммуногенных полимерных конъюгатов
NZ517012A (en) Peptides that lower blood glucose levels
ATE522563T1 (de) Verzweigte polyalkylenglykole
CA2286575A1 (fr) Compositions presentant une liberation prolongee et leur procede de preparation
AR027509A1 (es) Conjugados g-csf
DK0847278T3 (da) Parathyroideahormon-analoger
AU2713299A (en) Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ATE424431T2 (de) Verfahren zur herstellung von 1- benzotriazolcarbonatestern von wasserlöslichen polymeren
RU99124209A (ru) Композиции пролонгированного высвобождения и способ их получения
NZ592704A (en) Lyophilized recombinant von willebrand factor (rVWF) formulation comprising buffering agents, amino acids, stabilising agents and surfactants
RU2001123690A (ru) Ионные молекулярные конъюгаты биодеградируемых сложных полиэфиров и биоактивных полипептидов
CN108948144A (zh) 肽组合物的修饰以提高稳定性和递送效率
DE69932281D1 (de) Antimikrobiell wirkendes Peptid
CA2324901A1 (fr) Compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
ATE181732T1 (de) Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden
AR014621A1 (es) Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina
EP1763535B1 (de) Mit einem organischem rest verbundenes polypeptid
US20030139346A1 (en) Polymer stabilized neuropeptides
DE69736487D1 (de) Peptidzusammensetzung mit wachstumsfaktor-ähnlicher aktivität
DE60236796D1 (de) Verzweigte polyalkylenglykole
AU664855B2 (en) Lanthionine bridged peptides

Legal Events

Date Code Title Description
FC Application refused